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Abstract   
 
Despite global reductions in HIV incidence and mortality, the 15 countries of Eastern 
Europe and Central Asia (EECA) that gained independence from the Soviet Union in 
1991 is the only region where both continue to rise. HIV transmission in EECA is fueled 
primarily by injection of opioids, with harsh criminalization of drug use that has resulted 
in extraordinarily high levels of incarceration. Consequently, people who inject drugs 
(PWID), including people with HIV, HCV and tuberculosis, are concentrated within 
prisons. Evidence-based primary and secondary HIV prevention using opioid agonist 
therapies (OAT) like methadone and buprenorphine maintenance therapies and 
needle/syringe programs (NSP) are available in five and three EECA countries, 
respectively, with none of them meeting recommended coverage levels. Similarly, 
antiretroviral therapy (ART) coverage, especially among PWID, is markedly under-
scaled. Russia bans OAT and does not support NSP—with neither available in 
prisons—despite the country’s high incarceration rate and numbers of PWID and people 
living with HIV (PLH). Mathematical modelling for Ukraine suggests that high levels of 
incarceration in EECA countries enhances HIV transmission among PWID, with 28% to 
55% of all new HIV infections over the next 15 years being attributable to heightened 
HIV transmission risk among currently and/or previously incarcerated PWID. Additional 
analyses also indicate that at least 6% of all incident TB cases and 75% of incident TB 
cases in PWID are due to incarceration. Interventions that reduce incarceration itself 
and effectively intervene with prisoners to screen, diagnose and treat addiction and HIV, 
HCV and tuberculosis are urgently needed to stem the multiple overlapping epidemics 
concentrated in prisons.    
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Key Messages 
 Incarceration rates in Eastern Europe and Central Asia are among the highest in the 
world due to policies that concentrate people who use drugs and others at high risk 
for HIV, viral hepatitis and tuberculosis. 
 Due to policies within this region, the prevalence of HIV, HCV and tuberculosis 
infection is several-fold higher than in the surrounding community. 
 Analyses from Ukraine suggest that incarceration could be contributing up to half of 
all new HIV infections among people who inject drugs, and scaling up opioid agonist 
therapy within prisons and effectively transitioning them to the community would 
markedly reduce HIV transmission within this group.  
 Similarly, strategies that reduce incarceration of people who inject drugs in Ukraine 
would greatly reduce the number of new tuberculosis cases, underscoring the 
importance of screening, treatment and continuity of care for prisoners with or at risk 
for tuberculosis. 
 Armenia, Kyrgyzstan and Moldova have successfully introduced all 15 of the 
internationally-recommended HIV prevention strategies, including provision of opioid 
agonist therapy with methadone and needle and syringe programs – albeit 
inadequately scaled-to-need.   
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Introduction 
The negative and mutually reinforcing nature of incarceration, substance use 
disorders (SUDs), blood-borne viruses like HIV and HCV, and tuberculosis (TB) is 
especially problematic in the 15 UNAIDS-designated countries of Eastern Europe and 
Central Asia (EECA) and results in a concentration and deleterious interaction between 
these co-morbid health and social conditions.1,2 EECA is now the only region where the 
number of new HIV infections have increased annually from 120,000 to 190,000 
between 2010 and 2015, resulting in the number of people with HIV (PLH) increasing 
from 1.0 to 1.5 million.3 While new World Health Organization (WHO) guidelines 
recommend treatment for all PLH irrespective of CD4 count, coverage with antiretroviral 
therapy (ART) in the region is <10%4 and occurs with suboptimal screening for diseases 
and suboptimal coverage of evidence-based HIV prevention strategies like opioid 
agonist therapies (OAT) with methadone or buprenorphine and needle/syringe 
programs (NSP).5,6  
In EECA, proscriptive policies that promote arrest of socially vulnerable 
individuals at increased risk for HIV, viral hepatitis and TB, like people who inject drugs 
(PWID), men-who-have-sex with men (MSM) and sex workers, result in a concentration 
of risk within prisons, which amplifies disease and leads to onward infection in the 
community post-release.7 These epidemics converge in the EECA region, where abrupt 
and far-reaching social, economic and political transitions since the dissolution of the 
Soviet Union in 1991 have resulted in poor public health consequences. Where such 
negatively reinforcing comorbidities exist, effective HIV prevention and treatment must 
address all problems simultaneously to have a noticeable impact.1 Yet, the HIV 
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response remains inadequate as HIV incidence and mortality continue to increase in 
EECA, despite a reduction worldwide.3 
Although EECA countries are culturally and religiously distinct and underwent 
different political, economic and social trajectories since independence, they share 
socio-political, philosophical and organizational vestiges of the former Soviet Union, 
which now shape the evolving syndemics of mass incarceration, SUDs, HIV, HCV and 
TB. Aside from the high-income countries of Estonia, Lithuania and Latvia, the 12 other 
EECA countries are low/middle-income countries (LMIC). Following the Soviet Union’s 
collapse, in this setting of political and economic instability, heroin entered through new 
trade routes from Afghanistan.8,9 Injected heroin increased and led to explosive HIV 
transmission among PWID, where the epidemic remains mostly concentrated today. 
Harsh drug policies and criminalization laws ensued targeting PWID, with resultant 
mass incarceration, prison overcrowding10 and high incarceration rates (five of the top 
10 globally).11 The concentration of PWID, PLH with compromised immune systems and 
individuals with TB in criminal justice systems (CJS) created especially high-risk 
environments for HIV and TB transmission.12-14 The crumbling health infrastructure, 
unaccustomed to implementing HIV and TB prevention and treatment in prison settings, 
disregarded human rights recommendations.  
Data have not been comprehensively synthesized, however, to understand how 
the CJS contributes to the expanding HIV and related epidemics in EECA.  Here, we 
describe how incarceration, HIV, HCV, TB and SUDs converge to produce drug-related 
harm by applying the risk environment framework.15 Our analyses aim to understand 
how individual HIV-risk behaviours are embedded in social processes using the risk 
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environment framework, specifically, incarceration within EECA.15,16  Further, 
mathematical modelling and statistical analyses are used to assess the degree to which 
incarceration contributes to HIV and TB transmission among PWID in Ukraine and 
assesses the effectiveness of evidence-based HIV prevention strategies in reducing the 
harms of incarceration.  
METHODS 
[INSERT THIS NEAR HERE WITHIN THE METHODS SECTION] 
Comprehensive Review Search Strategy  
We conducted a comprehensive review of peer-reviewed publications and reports 
related to addiction, HIV, HCV, and TB treatment and prevention in CJS in the 15 
countries of EECA (Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, 
Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine, 
Uzbekistan). Key words and MeSH Headings related to incarceration (i.e., “inmate,” 
“prison,” “prisoner,” “detainee,” “criminal justice,” “pre-trial,” “detention,” “jail,” “SIZO,” 
“correctional,”) were cross-referenced with citations pertaining to each of the focus 
infectious diseases (“HIV”, “AIDS”, “HCV”,  “tuberculosis”) or SUDs (“heroin,” “opioids, 
“drug use”, “methadone”, “buprenorphine”, “substance ab/use,” “addiction”). We limited 
our search to articles that were published in English and Russian on PubMed and 
Google Scholar between January 1, 2012 and July 20, 2015. We retrieved and 
reviewed 1,837 unique citations, and 449 where selected for inclusion. Additional 
information from other sources was also included. We reviewed grey literature from 
websites in English, Ukrainian and Russian, including government-reported health 
status of prisoners in each country.  
 
Analytical Framework 
The aims of this comprehensive review are to: 1) review the historical features 
occurring during a devastating transitional period that shape the concurrent epidemics; 
2) present a theoretical framework for understanding how the CJS, including policing 
and incarceration practices, influences the evolving HIV and TB epidemics; 3) provide 
an analysis of up-to-date legal, criminal justice and epidemiological data from EECA 
countries; 4) use detailed data from Ukraine to estimate the degree to which 
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incarceration contributes to HIV transmission among PWID (using dynamic 
mathematical modelling) and TB transmission among PWID and the general population 
(using statistical analyses); and 5) recommend directions for future prevention, 
treatment and research.  
Here, we examine how the risk environment within the CJS mutually reinforces 
and concentrates the effect of several medical conditions (e.g., HIV, HCV, TB) in the 
CJS.  This is impacted by at least one social condition (e.g., incarceration) but also 
includes the policing practices that influence arrest and entry into the CJS and the 
experiences within the CJS environment itself, which result in the syndemic of social 
and medical co-morbidities. The amplification of drug-related harm in prisons17-19 is best 
understood using the conceptual framework of the risk environment framework.15 This 
framework posits that individual decisions about disease prevention and treatment are 
rooted in structural risk such as spaces (in this case, prisons) that, while exogenous to 
the individual, independently contribute to risk-taking and health-seeking behaviours. 
Hierarchical social structures within the CJS, interpersonal violence and the loss of safety, 
stigma, privacy and autonomy often limit decision-making by prisoners’, including choices 
about healthcare engagement and drug use.16,20 Access to prison-based HIV and other 
healthcare (like OAT) services, and the capacity to reduce drug-related harm, is influenced 
by these environmental factors, at the social, economic, and political levels.21  
Survey Methods 
In most EECA countries, access to accurate prison-related data and formal and 
informal operations of the penitentiary systems is limited. We therefore aimed: 1) to 
compile data on prisoner health and access to health services focusing on drug-related 
  9 
and co-morbid conditions; 2) to compile supplemental survey information from prison 
medical departments with assistance from UNODC using official governmental requests 
in each country. Among 15 surveys requested, 11 responded and findings are included 
in Tables 1 and 2.  
Evaluating the contribution of incarceration to HIV and tuberculosis transmission 
 We conducted dynamic HIV transmission modelling to assess the long-term 
contribution of incarceration to HIV transmission among PWID in Ukraine, and assessed 
the impact of reducing incarceration and scaling-up prison-based OAT. Additional 
statistical analyses assessing the contribution of incarceration to TB transmission in 
both PWID and the general population in Ukraine were used to estimate the contribution 
of current or recent incarceration to yearly TB transmission in these groups. Modelling 
and epidemiological methods and results are described in the Ukraine Case Study, with 
further details and model equations included in   Boxes 1 and 2 and the online 
appendices.  
Historical Framework, Organization of Criminal Justice and its Influence on 
Eastern Europe and Central Asia 
Governmental ministries other than the Ministry of Health administratively 
oversee the CJS in the EECA region, including healthcare delivery, in all EECA 
countries (Figure 1 and Table 2). Police oversight and arrest, with short-term detention 
in lock-up facilities, is overseen by the Ministry of Interior. Healthcare in pre-trial 
detention and prisons, however, fall under a variety of ministries. International 
organizations, however, support separating oversight of investigations and prosecution 
from the execution and supervision of criminal sanctions. Importantly, although the 
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WHO recommends that prisoner healthcare be consistent with community care 
standards, and overseen by the Ministry of Health,22 none of the EECA countries have 
adopted this recommendation. Some countries, however, have created separate 
ministries devoted specifically to specialized prisoner supervision.  
The CJS in all EECA countries, derived from the Soviet system, includes pre-trial 
detention centres, similar to jails and referred to as SIZO, where detainees remain for 
up to two years while awaiting sentencing. After sentencing, treatment is interrupted by 
transitional supervision for up to 2 months in etap, which is overseen by the Ministry of 
Interior, followed by placement in penal colonies (including lower security ‘settlement’ 
colonies and colonies for juvenile offenders) or prisons with cellblocks after sentencing. 
Each ministry responsible for oversight at various stages within the CJS, however, may 
have policies that conflict with the other (e.g., regarding allowance or provision of 
various services). Table 1 compares the infectious disease prevalence and harm 
reduction coverage in prisons and communities in each country. Table 2 and the 
expanded version in the appendix provide an overview of CJS facilities in each country 
based on our survey and published reports. Sentenced prisoners are generally divided 
into minimum, medium and maximum-security facilities, which we term “prisons.” 
Prisoners with HIV are not segregated but those with TB are isolated in dedicated, 
specialized TB medical wards.  
The legacy of Soviet-style addiction treatment, termed narcology,23 prevails in 
EECA countries and includes non-evidence-based measures like utilization of 
antidepressants, anxiolytics, antipsychotics, excessive physical exercise, neurosurgery 
and kinesio-therapy to treat addiction. In Russia, the only criterion of successful 
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addiction treatment is complete abstinence from any psychoactive substance, including 
from physician-prescribed methadone and buprenorphine, which are part of the WHO 
list of essential medications that remain banned throughout the country. These 
measures follow the Soviet-era models of repressive psychiatry, contrary to 
international standards, 24 and often amount to suffering, discrimination and humiliation 
for drug-dependent people (see Panel 2). Prison staff often harbour negative attitudes 
toward OAT and consider drug dependence a social problem and with resultant criminal 
behaviour rather than a chronic, recurring illness.25 Despite elevated HIV within prisons, 
the legal framework across EECA often falls short of human rights mandates for 
ensuring access to evidence-based addiction and HIV services within the CJS. OAT 
with methadone or buprenorphine is internationally-recognized as the most effective 
treatment for chronic, opioid dependence and is also among the most effective primary 
and secondary HIV prevention strategies available.1,26 Moreover, mathematical 
modelling suggests that OAT expansion is the single most cost-effective means of 
controlling the HIV epidemic in EECA,27 but when combined with ART scale-up, it is 
more effective but also more costly.28 Regional policies (Tables 1 and 2) vary on whether 
OAT is provided throughout the entire incarceration (Moldova, Armenia and Kyrgyzstan; 
see Panel 1), upon entry to police-lockup with supervised withdrawal (Georgia, 
Lithuania, Latvia, Estonia and Ukraine), only in the community (Belarus, Azerbaijan, 
Tajikistan and Kazakhstan) or not at all (Russia, Uzbekistan and Turkmenistan). 
Moreover, contradictory legal mandates lead to an uneven distribution of care. In 
Ukraine, although national drug policies necessitate harm reduction programs (including 
OAT and NSP) for all PWID, the medical guidelines require current signs of physical 
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dependence, which are not always evident after a detainee completes withdrawal in 
police lockup or in SIZO, disqualifying convicted prisoners from treatment.  
An Overview of Mass Incarceration, Substance Use Disorders, HIV, HCV and 
Tuberculosis Infections  
Mass incarceration 
 The dramatic rise and interrelationship between incarceration, HIV, HCV and 
tuberculosis in EECA is multifactorial.29-32 The Soviet collapse gave rise to numerous 
factors that independently and collectively contributed to unprecedented mass 
incarceration in all EECA, in part, as a result of decreasing industrial output, living 
standards, and life expectancy.4 EECA, with 1.1 million prisoners, has some of the 
highest incarceration rates globally,11 giving rise to the term “criminological transitions” 
for EECA countries.33 Although incarceration rates have decreased modestly over the 
past decade, thirteen of the fifteen EECA countries still have rates that exceed the world 
average of 146 prisoners/100,000 population, with ten exceeding 200: Turkmenistan 
(583), Russia (455), Belarus (335), Lithuania (315), Georgia (281), Kazakhstan (275), 
Latvia (264), Azerbaijan (236), Estonia (218) and Moldova (212); Ukraine recently 
plummeted from 324 to 195 due to regional conflicts.11 This mass incarceration is the 
result of several intersecting factors, which have converged to result in some of the 
highest general population prevalences of HIV,34 HCV35 and tuberculosis, including 
multi-drug resistant tuberculosis (MDR-TB),12 in the world,29,31 concentrated further 
within prisons where rates are substantially higher. 
 
Substance use disorders 
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After 1991, injectable opioid use increased markedly due to changes in drug 
routes from Afghanistan and economic collapse promoting a new drug economy.8,36 
Consequently, volatile opioid injection and HIV epidemics followed.10 A number of harsh 
criminal sanctions toward PWID ensued, resulting in escalating incarceration rates, 
especially of PWID who either had or were at high risk for HIV. Moreover, with the 
backdrop of economic instability and low wages for public servants like police, PWID 
became targets for bribes and other forms of corruption. Inability to pay resulted in 
arrest, detention, and imprisonment.37,38 Consequently, PWID represent over one third 
of prisoners in EECA, but may be as high as 50% to 80% in some EECA countries.39-42 
Explosive HIV transmission dynamics accompanied the growing number of PWID 
and incarceration rates in EECA, with HIV incidence and HIV-related mortality 
remaining volatile and increasing. Although HIV is concentrated among PWID and their 
sexual partners, there is evidence of transmission among sex workers and MSM.43 By 
year-end 2013, there were over 1.4 million PLH in EECA, with over 85% residing in 
Russia and Ukraine.44 Despite recent evidence of modestly expanded HIV prevention 
programs in some EECA countries, coverage with ART (especially among PWID), OAT 
and NSP remains low.5,6 Also, extensive migration between and within some EECA 
countries results in lack of access to HIV prevention on the basis of citizenship or official 
registration for governmental healthcare.40,43  
 
HIV  
Prisons present as structural risk environments (Figure 2) due to the high 
concentration of PWID, HIV and HCV.34 HIV prevalence in prisoners is high throughout 
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EECA. While no reliable data exist for Turkmenistan and Belarus, HIV prevalence 
exceeds 10% in four countries - Latvia (20.4%), Ukraine (19.4%), Estonia (14.1%) and 
Kyrgyzstan – but remains markedly higher than in the community in Uzbekistan (4.7%), 
Lithuania (4.1%), Kazakhstan (3.9%), Azerbaijan (3.8%), Armenia (2.4%), Tajikistan 
(2.4%), Moldova (1.9%) and Georgia (0.4%). In nationally representative prison 
surveillance studies, HIV prevalence is 22-fold, 19-fold, and 34-fold higher in prisons 
than in surrounding communities in Ukraine,39,45 Azerbaijan40 and Kyrgyzstan,41 
respectively. Factors contributing to this concentration include harsh policies and laws 
toward PWID, police targeting PWID and within prison-drug injection. In Russia, nearly 
all drug-related convictions are for drug use rather than drug trafficking.46  
Estimates of within-prison drug injection range from 3-53%,17,18,47,48 and have 
contributed to volatile HIV transmission within prisons in the region,49 a sobering 
consequence of the overrepresentation of PWID and untreated SUDs within prison. 
Evidence suggests that PWID inject less frequently in prisons than outside, but HIV 
transmission risks are markedly elevated within prisons because injection equipment is 
scarce with increased high-risk sharing.18 This may, in part, contribute to findings that 
prior incarceration is independently associated with HIV among PWID in community 
settings,50 which we also found in our Ukraine Case Study (Figure S9 in online 
appendix). Moreover, few studies have examined within-prison drug injection in EECA, 
but data from HIV-infected Ukrainian prisoners showed extraordinarily high levels (54%) 
with many injection-sharing partners.17  
HIV treatment is effective HIV prevention and must include prisoners,51 many of 
whom are PWID.52 Achieving UNAIDS 90-90-90 targets requires improved screening, 
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treatment and adherence outcomes53 in EECA countries. Despite National AIDS 
Centres in some countries reporting high ART coverage levels in prisoners who are 
diagnosed,42,54 the majority of PLH remain undiagnosed within EECA prisons. Only half 
of PLH in Ukrainian and Kyrgyz prisons are diagnosed before leaving prison.39,41,45 In 
Ukraine, fewer than 12% of PLH were aware of having HIV, with another 40% being 
diagnosed during incarceration, leaving almost half still not aware of their status.45 In 
Azerbaijan, however, HIV diagnosis approaches 75%.40 While both Azerbaijan and 
Kyrgyzstan provide high ART coverage for PLH who are diagnosed,40,41 fewer than 4% 
of PLH in Ukrainian prisons receive it.39,45 No EECA country has data for ART coverage 
post-release, but even data from high-income countries suggest that the transition 
period from prison is one of heightened vulnerability when ART coverage falls 
precipitously and HIV risk is high,55 especially for women.56,57 
Hepatitis C Virus 
One review reported HCV prevalence among prisoners ranging from 3.1% to 
38.0%,35 with the highest in Central Asia.58 Representative prison biosurveillance 
studies show HCV prevalence to be substantially higher in Ukraine (60.2%),39 
Kyrgyzstan (49.7%),41 and Azerbaijan (38.2%),40 even though self-reported lifetime 
injection prevalence was substantially lower. These data suggest drug-injection is often 
under-reported in surveys. HCV infection in PLH, when left untreated, complicates HIV 
treatment1 and is associated with accelerated liver fibrosis.59 New direct-acting antiviral 
HCV treatments have low toxicity, short treatment durations, and can cure HCV in over 
90% of patients, irrespective of HIV status.60 Restricted by affordability, the only EECA 
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prisoners in EECA receive HCV treatment in prisons is in Georgia where an HCV 
elimination strategy is underway.61 
Tuberculosis 
Prisons generally, and especially in EECA, promote TB transmission, particularly 
drug-resistant strains, primarily because of crowding that increases contact between 
large numbers of high-risk persons in poorly ventilated facilities over extended 
periods.12,13 Furthermore, tuberculosis control is complicated by low cure rates due to 
delayed diagnosis, ineffective screening, isolation and treatment in prisons, perverse 
environmental disincentives (see Panel 2) to start or continue treatment (better housing, 
treatment or food, being excused from harsh work, profiting from the sale of TB 
medications).62-64 Incarcerated individuals are at higher susceptibility for tuberculosis 
(poverty, SUDs, homelessness, malnutrition and HIV infection) and are often released 
to the community before treatment completion, without effective transitional care.12,65-67 
Factors contributing to tuberculosis transmission include overcrowding, high 
prisoner turnover, limited access to healthcare services, delayed case detection and 
poor contact detection, lack of recommended rapid diagnostic methods like Xpert 
MTB/RIF, and suboptimal treatment of infectious cases and implementation of 
tuberculosis infection control measures.65-67 MDR-TB is disproportionately prevalent in 
EECA prisons68,69 because of high MDR-TB prevalence in the community70-73 and large 
numbers of HIV-infected PWID who are more susceptible to tuberculosis due to being 
immunocompromised.74 The Ukraine Case Study illustrates the large degree to which 
incarceration contributes to tuberculosis transmission in EECA, with it’s tuberculosis 
incidence rates being directly correlated with increasing mass incarceration.12 
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Additionally, MDR-TB incidence in EECA after independence was directly correlated 
with increasing mass incarceration.12   
The Soviet Union collapse resulted in inadequate funding and supply of first-line 
TB regimens and extended confinement that facilitated transmission within prisons.75 In 
Belarus, MDR-TB strains are 35.3% of new and 76.5% of previously-treated TB cases, 
meaning that half of all TB cases are MDR-TB.69,76 Incarceration and HIV are 
independent contributors to patients having MDR-TB strains.69 Remarkably high levels 
of MDR-TB cases also exist in Russia,77,78 Lithuania and Latvia,78 and Ukraine.79 
International guidance for TB screening and treatment80 is inconsistently deployed in 
prisons throughout EECA with resultant poor outcomes.65,67 One notable exception is 
Azerbaijan which reduced both TB and MDR-TB cases through the effective 
implementation of the WHO’s Stop TB Strategy in the penitentiary sector, which 
involved routine screening, specialty TB hospitals, new infection control measures, rapid 
diagnostic testing, and training of prison personnel who now train prison staff elsewhere 
in EECA.81   
Case Study: Modelling the Impact of HIV and TB transmission in Ukraine - a 
Country in Conflict 
Ukraine, a middle-income country of 31 million, is in the midst of conflict and has 
the highest prevalence of HIV in adults (1.2%), with tuberculosis and MDR-TB 
contributing the most to HIV-related mortality.3 Before Ukraine’s conflict with Russia 
over Crimea and the Donbas region, Ukraine’s incarceration rate per 100,000 
population was 324, but recently dropped to 195 per 100,000 in 2014 with large 
numbers of prisoners rapidly released to the community, increasing numbers of arrests 
  18 
and initiation of a new probation system that now supervises 70,000 people in the 
community. Incarceration among PWID in national surveys, however, does not appear 
to have decreased from 2011-2015.82,83 HIV prevention services in Ukraine are under-
scaled with only 2.7% of 310,000 PWID prescribed OAT and 20% of PLH prescribed 
ART. ART coverage in HIV-infected PWID, however, remains under 5%.5 Globally and 
within EECA, PWID experience high levels of incarceration (lifetime: 40%-85%),84,85 and 
current or previous incarceration is associated with heightened injecting risks and 
increased HIV and HCV transmission.86-88 In Ukraine, minimally 52% of PWID have 
been incarcerated,89-91 with previously incarcerated PWID reporting an average of 5 
incarcerations, each a year in duration.39,89,91    
Data from three recent national surveys among PWID and current prisoners in 
Ukraine were used for epidemiological analyses and HIV transmission modelling, 
described briefly in Boxes 1 and 2 and further in the online appendices. These data 
suggest that previously incarcerated PWID have a significantly higher HIV prevalence 
than never incarcerated PWID (28% versus 13% - see Figure S9), even after 
controlling for injecting duration (aOR=1.8; 95%CI=1.6-2.1). Additionally, they have 
heightened HIV risk behaviours, with previously incarcerated PWID reporting 3.9 
(95%CI=2.8-5.0) more injections per month,89 and a 1.5-fold (95%CI=1.3-1.9) greater 
chance of sharing syringes89 than never incarcerated PWID, even after controlling for 
injecting duration. Recently incarcerated PWID (past year) had an even greater 
likelihood of syringe-sharing (aOR=2.2; 95%CI=1.6-3.0).45,92 Similarly, currently 
incarcerated PWID have over twice the HIV prevalence of never incarcerated PWID 
(28.5% versus 12.8%)39,45 and high rates of syringe-sharing.17,37 Together, these data 
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suggest that incarceration and the post-release period are important contributors to HIV 
transmission among PWID in Ukraine and forms the basis for our HIV modelling (Box 
1).39,45 This modelling suggests that incarceration, and specifically the heightened 
injecting risks post-incarceration could contribute 55% of new HIV infections among 
PWID in Ukraine over the next 15 years if we assume all this elevated risk is attributable 
to incarceration, or 28% if we conservatively assume that only the heightened risk 
among recently released PWID is due to incarceration (Figure 3 and 4). Conversely, 
reduced incarceration of PWID is unlikely to substantially decrease new HIV infections 
over 15-years due to the remaining elevated risk among previously-incarcerated PWID. 
Scaling-up and continuing prison-based OAT post-release, however, could avert 19.8% 
of HIV infections over 15 years because it directly reduces the heightened post-release 
risk (Figure 3 and 4).  
TB incidence across EECA is high (nearly all over 100 per 100,000 population), 
and are positively correlated with country-level incarceration rates,12 highlighting the 
importance of within-prison TB transmission to the countrywide epidemics. An 
ecological analysis estimated that across EECA, each percentage point increase in a 
country’s incarceration rate corresponded to a 0.34% increase in TB incidence 
(95%CI=0.10%-0.58%).12 A systematic review suggests that TB incidence in LMICs is 
10 to over 30 times greater within prison than in the community.93 Few studies, 
however, have estimated the contribution of incarceration to the TB epidemic in EECA, 
with the systematic review estimating that between 5% and 17% of TB cases in Russia 
could be due to exposure within prison.93 We therefore conducted in-depth statistical 
analyses using the same datasets utilised for the HIV modelling91 to evaluate the role of 
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incarceration for increasing TB disease risk among the general population and PWID in 
Ukraine (Box 2). These analyses suggest that incarceration is an important contributor 
to TB transmission (Figure 5), and could be responsible for three-quarters of new yearly 
TB infections among PWID and 6.2% of all yearly TB infections in Ukraine. 
 
Risk Environment Framework for Criminal Justice Settings in the Region 
Figure 2 provides an overview of the risk environment factors in both the 
community and CJS that contribute to onward disease transmission in EECA. The high 
prevalence of these infections in the community, coupled with both micro-level and 
macro-level factors embedded within the physical, social, economic and policy/legal 
framework, result in the concentration of high-risk key populations like PWID and sex 
workers in the CJS. Incarceration, a physical factor, further amplifies these conditions 
by concentrating individuals with these infections. It also disrupts injection and social 
networks, a social factor, by creating new and riskier networks that develop as a 
survival tactic during incarceration.94 Policy factors forbidding OAT and NSP in 
Ukrainian prisons, where HIV prevalence is high (19.4%),39 HIV detection and ART 
coverage is low,45 facilitate frequent sharing of injecting equipment by PWID17 and likely 
fuels HIV and HCV transmission.17,39,41,45 Similarly, individuals released from prison are 
highly stigmatized (social factor), relapse to drug use quickly (policy factor), develop 
new injection networks (social factor), and policing efforts target PWID and former 
prisoners due to registration of PWID in the community (policy factor).37 Our analyses 
from our Ukraine Case Study suggest that the prison risk environment contributes to 
both HIV and TB transmission in PWID and TB transmission more generally to the 
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community. Moreover, introducing OAT to 50% of PWID within prison and retaining 
them in treatment for 12 months post-release would most-effectively reduce HIV 
incidence over the next 15 years, suggesting that this risk environment can be greatly 
influenced by the introduction of evidence-based addiction treatment.   
Drug-related policies 
Key populations face numerous legal barriers that simultaneously contribute to 
incarceration and to accessing essential HIV programmes and services.95,96 Drug 
policies vary considerably. In seven EECA countries (Russia, Uzbekistan, Ukraine, 
Belarus, Moldova, Lithuania and Latvia) official names-based “registration” of PWID is 
required to receive treatment, including OAT. Registration, however, often results in 
restrictions in employment, loss of privileges (e.g., driver’s license) and targeting by 
police.37,97,98,99 Moreover, a passport and an official address is required for employment 
in Ukraine, undermining economic stability.98 Collectively, these restrictions perpetuate 
reincarceration,100 especially given that alternatives to incarceration are uncommon in 
any EECA country.  Addiction experts are required to report anyone accessing services, 
including for diagnosis confirmation, registration and treatment. In most registries, there 
is little guidance or criteria to remove names from the registry or how recovery is 
defined. In Moldova and Uzbekistan, PWID are monitored for three years before 
removal from the registry is considered. In Uzbekistan, removal from the registry occurs 
upon incarceration. Otherwise, name-based registries persist for life.  
Six countries have a mix of administrative and criminal penalties for drug 
possession. In Kazakhstan, administrative procedures can be deployed twice-annually 
for drug possession, after which arrest and criminal sanctions ensue. In Kyrgyzstan, 
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these penalties differ based on the quantity of illicit drugs found. Elsewhere, 
administrative procedures are used for limited personal use amounts although the 
amount varies. In all countries, the criminal code defines the purchase of illicit drugs as 
an incarcerable criminal offense.  
Punitive drug laws restrict access to HIV testing and treatment for PWID. 
Criminalisation of drug use and discriminatory practices restrict access to NSP and 
community agencies where these services are located. Harm reduction services are 
often legally restricted to adults. Police in some countries arrest PWID who access harm 
reduction services and confiscate drugs and syringes or extract bribes for the 
possession of syringes or needles.37,38,101,102 In one Russian survey of PWID, over 60% 
had been arrested for needle possession or had drugs planted on them by the police.103  
Sexual Activity Policies 
 While many EECA countries have repealed laws prohibiting same-sex 
relationships, Uzbekistan and Turkmenistan continue to enforce them. Tajikistan, 
Uzbekistan, Ukraine and Armenia have laws that criminalize sex acts between 
consenting adults of the same gender, sodomy, “cross dressing” or “gender 
impersonation”.  Kyrgyzstan and Tajikistan have legislation where the age of consent 
differs for homosexual and heterosexual sex; Kyrgyzstan has laws or policing practices 
criminalizing or preventing condom distribution yet supplies them within prison.  Though 
transparent in their intent to target and stigmatize MSM, Russia enacted legislation 
prohibiting dissemination of “propaganda of non-traditional sexual relations [i.e., LGBT] 
among minors” to protect '"traditional" family values, These laws result in arrest of 
individuals promoting HIV prevention for MSM. Similar but harsher legislation is being 
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considered in Belarus, Kazakhstan and Kyrgyzstan.43 
All EECA countries prohibit sex work, but police enforce it variably and target sex 
workers who use drugs. Kyrgyzstan, Azerbaijan and Uzbekistan have laws or policies 
allowing mandatory HIV testing of key populations.  Some countries (Kyrgyzstan, 
Tajikistan, Uzbekistan, Ukraine and Armenia) have laws that protect against human 
rights violations but they are not specific to HIV or key populations. 
Community supervision 
Community sanctions like probation or drug courts are not widely available, and 
probation is not generally linked to treatment.  Several countries have limited 
community-based supervision, including Russia (supervision by former military/prison 
personnel), Ukraine (new in 2015), Moldova (started 2002), Latvia (started in 2005), 
Estonia (started in 1998 with expansion in 2013), Lithuania, Georgia and Kazakhstan. 
Pilot projects are underway in Armenia to guide probation service initiation.  Some 
probation programs refer cases to drug treatment agencies or psychiatric hospitals. 
Many of the probation programs emerged from the prison service and therefore reflect 
the prison culture. In most instances, probation is in its infancy.   
Coverage with Opioid Agonist Therapies 
Many prisoners in EECA not only initiate drug injection within prison, but continue 
to share injecting equipment during incarceration17,41 and especially post-release.17 Five 
countries (Armenia, Kyrgyzstan, Moldova, Latvia and Estonia) have OAT in prisons, 
with coverage being extremely low. Georgia has a pilot program in SIZO and four others 
offer it only in police-lockup (Table 1 and Figure 6).  Emblematic for the region, 
Ukraine’s prison personnel have especially negative attitudes toward OAT, but is 
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improved when sufficiently knowledgeable about its benefits,25 while prisoners have 
higher expectations about recovery that diminish post-release in the absence of OAT.104 
In Moldova, OAT and NSP exist within communities and prisons, but OAT coverage is 
disproportionately lower in the community than in prisons, reducing access post-release 
and necessitating many OAT patients to discontinue OAT before release. In Moldova, 
PWID on OAT are often ostracized within the prison risk environment perhaps due to 
within-prison illicit drug economies that compete with OAT.25,105 Thus, effective and 
essential OAT scale-up must educate and motivate both prisoners and personnel.  
HIV diagnosis 
The first step to achieving the UNAIDS 90-90-90 HIV treatment as prevention 
strategy is HIV testing.53 Most EECA prisons deploy risk-based opt-in testing within 
prisons. One of the major challenges in EECA prisons is low HIV detection, where over 
half of HIV-infected prisoners do not know their HIV status.39,41,42,45 For those that do, 
however, most are tested within prison.39-41,45 Notable exceptions where expanded HIV 
testing greatly improved HIV diagnosis include Estonia106 and Azerbaijan.40 Required 
name-based HIV registries often undermine voluntary testing efforts and treatment 
engagement.97,107 Officially reported HIV data therefore underestimates108 true 
prevalence and restricts access to HIV treatment due to mandatory registration 
combined with stigma, discrimination and criminalization of key populations.6,97,107 
Similarly, OAT patients must be officially “registered” before receiving it, which can lead 
to restrictions on employment opportunities, limitations in housing, and revocation of 
drivers’ licenses, which further compounds economic disparities.107  
Conclusions 
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 The 1990 United Nations Basic Principles for the Treatment of Prisoners state 
that prisoners “shall have access to the health services available in the country without 
discrimination on the grounds of their legal situation.”109 This basic principle has been 
expanded in the case of HIV to also include preventive services, but has been 
infrequently applied, especially in many EECA countries where prisoners derive less 
benefit from prevention and treatment services than other citizens.110 Structural aspects 
of the CJS in EECA concentrate most at-risk populations, which, taken together, likely 
contribute heavily to disease amplification and transmission within prison and to the 
community post-release. These structural impediments also limit access to prevention 
and treatment services for HIV, HCV and TB.  Findings here suggest that the high-risk 
prison environment, including the immediate period post-release (for HIV), is an 
important contributor to HIV and TB transmission to PWID and more broadly for TB 
transmission to the general population. Strategies that reduce incarceration overall, 
especially for PWID and greatly expand OAT within prison and effectively continue it 
post-release are likely to have the greatest impact on HIV and TB transmission in PWID 
interfacing with CJS. Strategies that reduce incarceration for the entire population, but 
especially for PWID, are likely to reduce tuberculosis cases. Not only are policy reforms 
necessary to abrogate this trajectory, but further epidemiological, qualitative, modelling, 
cost-effectiveness and implementation science research is crucial to help ensure that 
both prisoner and public health is optimized and consistent with human rights mandates 
(Panel 3). Such approaches could reduce the transmission of HIV, HCV and TB in 
these settings especially if they also ensure continuity of care following release from 
prison. 
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Box 1: Modelling the Impact of Incarceration and Scale-up of Opioid Agonist 
Therapies in Prisons on HIV Transmission among People Who Inject Drugs in 
Ukraine  
*References 111 and onwards in Ukraine Case Study are available in the online 
appendix 
A national, dynamic model of incarceration and HIV transmission through drug 
injection among PWID was developed, that stratified PWID by incarceration state 
(never, current, recently released within last 12 months, and past incarceration over 12 
months ago), and HIV infection state (susceptible, initial acute and chronic HIV 
infection, and receiving ART). Within a Bayesian framework,111 the model was 
calibrated to detailed national data on the incarceration of PWID (Table S1),39,45,91,92,112 
and HIV prevalence (Table S3) among never (11.9%–13.6%), current (22.2%–35.4%), 
and previously incarcerated PWID (26.6%–29.7%).39,45,92 Based on the same national 
data, this calibration assumed elevated injection-related HIV transmission risk among 
previously incarcerated PWID (relative risk 1.9-3.3 within 12-months post-release and 
1.4-2.0 thereafter) compared to never incarcerated PWID. Sensitivity analyses relaxed 
this assumption. Due to insufficient data, a non-informative prior was used for the 
transmission risk among incarcerated PWID.  
To estimate the long-term population attributable fraction (PAF) due to 
incarceration, the relative decrease in new HIV infections over 15 years was projected if 
the transmission risk among currently- and previously-incarcerated PWID were set to 
the same as never-incarcerated PWID. A conservative PAF assumed the transmission 
risk among recently-released PWID was the same as previously but not recently-
incarcerated PWID. We also examined how OAT scale-up to 50% of incarcerated 
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PWID, with 12-month OAT continuity post-release, could reduce HIV transmission. The 
supplementary materials provide more methodological details. 
When assuming heightened HIV transmission risk in previously incarcerated 
PWID, the model (Figures 3 and 4) suggests that community HIV incidence and 
prevalence would decrease dramatically by 2030 (by 75%; 95%CrI=64%-87%, and 
56%, 95%CrI=42%-66%, respectively) if the HIV transmission risk among currently- and 
previously-incarcerated PWID were set equal to never-incarcerated PWID. Additionally, 
55.1% (95%CrI=40.2%-68.2%) of new HIV infections would be prevented, mainly due to 
reducing the heightened risk among recently-released PWID. Indeed, 28.2% 
(95%CrI=13.6%-41.1%) of HIV infections would be averted if this heightened risk was 
only partially reduced to the same as non-recently incarcerated PWID. These findings 
were robust to making less restrictive assumptions about the relative transmission risk 
among previously incarcerated PWID. By contrast, if PWID had no new incarcerations 
after 2015, only 12.8% (95%CrI=-4.7-24.6%) of new HIV infections would be averted 
thereafter. If prison-based OAT were initiated in Ukraine, however, our modelled 
scenario suggests 19.8% (95%CrI=14.6%-24.5%) of HIV infections would be averted 
during 2015-2030, and community OAT coverage would increase by 8.3%. Much of this 
impact is due to benefits of retaining prisoners on OAT post-release, with only 5.6% 
(95%CrI=1.6%-8.3%) of HIV infections being averted without OAT continuation. Further 
projections suggest that community OAT (without prison-based OAT) coverage levels of 
28% (95%CrI=20%-33%), 48% (95%CrI=43%-50%) or 16% (95%CrI=12%-21%) would 
be required to achieve the same impact as scaling-up prison-based OAT, depending on 
whether this community OAT was untargeted or targeted to never- or previously-
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incarcerated PWID, respectively. Considering the prevention benefit per PWID on OAT, 
the prison-based OAT scenario is as efficient as targeting OAT to previously 
incarcerated community PWID, but is 1.6 and 3.2 times more efficient than untargeted 
community OAT and OAT targeted to never-incarcerated PWID, respectively.  
These analyses suggest incarceration is a driver of HIV transmission among 
PWID in Ukraine, with 55.1% (95%CrI=40.2-68.2%) of incident HIV infections possibly 
attributable to incarceration if we assume all the elevated risk among previously 
incarcerated PWID results from incarceration, or 28.2% (95%CrI=13.6-41.1%) if we 
conservatively assume only the additional risk among recently released PWID is due to 
incarceration.  
Importantly, increases in risk behaviours post-incarceration fuel the HIV epidemic 
in Ukraine’s PWID, highlighting the need to strategically target HIV prevention 
interventions to previously-incarcerated PWID. Findings here, and confirmed elsewhere, 
suggest prison-based OAT expansion with effective community transition post-release 
could be an effective strategy of achieving this.113-116 Strategies that reduce 
incarceration, like alternatives to incarceration (e.g., probation, drug courts), community 
policing that promotes treatment over arrest and changes in drug criminalisation policies 
should also be considered, although the HIV benefits may be less. 
Our analyses have limitations (supplementary materials), most specifically 
related to whether the elevated transmission risk among previously-incarcerated PWID 
is due to incarceration or higher-risk PWID being incarcerated frequently; future studies 
should examine longitudinal changes in risk before, during and after incarceration.     
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Box 2: Modelling the Impact of Incarceration on Tuberculosis Transmission in 
People Who Inject Drugs and More Broadly to the General Population in Ukraine 
 
*References 111 and onwards in Ukraine Case Study are available in the online 
appendix 
 
Statistical analyses (See online TB supplement for detailed methods) were 
performed using national survey data to assess the short-term yearly contribution of 
incarceration to recent and lifetime TB transmission among both PWID and the general 
public in Ukraine. Data sources included country-wide data from 1,612 PWID in the 
2015 ExMAT survey and 402 prisoners in the 2011 PUHLSE survey (see online 
appendix).  ExMAT provided individual-level data on incarceration (ever, total time), HIV 
status, drug injection duration, and TB status in last 12 months and ever. PUHLSE 
provided individual-level data on age, total time incarcerated, HIV status, ever-injected 
drugs, and ever TB status. Self-reported TB status was used for all analyses using a 
highly-validated survey question.117  
Using both datasets, linear regression models were firstly developed to evaluate 
the relationship between ever and recent TB status and ever being incarcerated or total 
duration of incarceration. Two survival models were then fitted to data on cumulative TB 
risk as a function of time in prison. Using the estimated hazard, an average TB 
incidence rate was estimated for each year of incarceration among prisoners (PUHLSE) 
or previously incarcerated PWID (ExMAT). The estimated incidence rate among 
prisoners (PUHLSE) and data on self-reported recent risk of TB (ExMAT) were then 
used to estimate the relative risk of TB among incarcerated PWIDs or prisoners overall 
compared to non-incarcerated PWIDs or the community as a whole,118 and the 
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population attributable fraction (PAF) of incarceration to overall TB risk and TB risk 
among PWID were estimated using standard formula.  
Our analyses consistently suggest that incarceration contributes significantly to 
TB transmission in Ukraine. After controlling for age, injecting duration and other 
variables; we estimate that for every additional year of incarceration there is a 13% 
(95%CrI 8%-17%) relative increase in TB prevalence among the overall population and 
a 6% (95%CrI 3%-10%) relative increase in TB prevalence among PWID (Figure 5).  
Although only 0.5% of the adult population was incarcerated, we estimate that 
6.2% (95%CI=2.2%-13.4%) of all incident TB cases result from incarceration. 
Conversely, among PWID this increases to 75% (95% CrI=51%, 94%) for HIV-infected 
PWID and 86% (95% CrI=56%, 98%) among HIV-negative PWID (See online appendix 
for details). 
Our analyses from Ukraine indicate that the contribution of incarceration to TB in 
the general population was similar to findings from Russia,93 and provides new insights 
that suggest a markedly higher PAF of incarceration to TB transmission among PWID. 
Although data suggest the importance of incarceration for TB,12,93,119,120 there is a 
paucity of data surrounding the contribution of prison to TB incidence in LMIC, 
especially in EECA where TB incidence is high. Nevertheless, other studies and data 
presented here indicate that prisons contribute substantially to TB epidemics broadly, 
but especially in PWID in this region (Panel 2: Sasha’s Story). While strategies that 
reduce incarceration for PWID would have the greatest impact, these findings also 
underscore the need to develop cost-effective interventions to diagnose, treat, and 
prevent TB transmission among incarcerated populations. Azerbaijan has emerged as a 
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regional leader in implementing such programs81 where they have adopted TB 
prevention activities within prison (screening, early detection and treatment, case 
isolation and preventive therapy for latent tuberculosis infection). Such strategies, 
especially if focused on PWID, should address the increased TB transmission risk 
associated with current and/or previous incarceration. Such strategies, including HIV 
prevention and treatment, are urgently needed to control the HIV and TB epidemics in 
Ukraine and other EECA settings. 
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Panel 1: Candles Burning in the Night  
Despite its well-documented efficacy in both prisons and communities, three 
EECA countries (Russia, Uzbekistan and Turkmenistan) legislatively ban any type of 
OAT, while the remainder provide it in the community. Harsh criminalization policies that 
result in high incarceration rates and large numbers of PWID in EECA prisons, 
compounded by high levels of documented within-prison drug injection in the region, 
extraordinarily high levels of HIV, viral hepatitis and TB and MDR-TB persist, Despite 
these poor prognostic indicators, a few countries have prevailed over the misaligned 
ideological policies espoused by Russia that favour punishment over rehabilitation and 
implemented internationally recognized evidence-based HIV prevention and treatment 
for prisoners.   
For example, small and financially vulnerable countries like Kyrgyzstan, Moldova 
and Armenia have introduced all 15 internationally-recommended HIV prevention 
strategies in prisons,121 including both OAT and NSP.  These countries have emerged 
as beacons in the region and have boldly introduced such programs despite external 
influences to ban them altogether, albeit suboptimally scaled, but have done so with 
external funding from international donors. These successful programs, however, may 
soon be jeopardized by anticipated loss from international donors. Moreover, as Russia 
is increasingly exerting external pressure and creating new political and trade alliances 
with some former countries of the Soviet Union, they too extend their ideological 
principles and financial support in ways that could eventually threaten and undermine 
the successes made by these public health and human rights-based HIV prevention 
interventions in prisons.   
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It is conservatively estimated that one-third of all prisoners in Kyrgyzstan, 
Moldova and Armenia are PWID (approximately 6,900), primarily of opioids. Yet, only 
802, or 11.6% are prescribed OAT. OAT introduction and even scale-up is minimally 
restricted by cost, since methadone is extremely inexpensive. While its efficacy is well-
substantiated, OAT policy is shaped more by ideology and prejudices against OAT than by 
scientific evidence.122,123 Despite these ideological influences in the region, five countries 
(Armenia, Moldova, Kyrgyzstan, Latvia and Estonia) have successfully introduced and 
expanded OAT throughout their CJS, including in pre-trial detention (See Table 2).  Recent 
findings from Moldova, which may be emblematic of prison-based methadone problems in 
the region, suggest that myths about and prejudices toward OAT are amplified within prisons 
and result in bullying and ostracism of OAT patients, and may undermine OAT expansion 
efforts.105 In nearby Ukraine, where OAT is not available within prison, extremely 
negative attitudes toward OAT prevail among prison personnel, but recent findings 
suggest that provision of accurate information and training may in part overcome these 
myths.25,104 Because the within prison risk environment is shaped by PWID, non-PWID, 
prison personnel and real and enacted policies for the setting, the next generation of 
OAT expansion efforts will therefore need to address multiple factors including these 
myths and prejudices and the within prison drug economy that likely propagates such 
myths to both incarcerated PWID and to prison personnel who may view OAT as 
competition for the illicit drug trade. Continued support for OAT and NSP must therefore 
not only address service delivery itself, but include strategies that combat 
misinformation and prejudices.  Continued funding and provision of comprehensive 
prevention strategies are crucial for sustainability and should be coupled with shared 
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best-practices with other EECA countries that seek to align human rights and public 
health mandates in both community and criminal justice settings.   
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Panel 2: Sasha* and the Ravages of Incarceration 
Prisons here in Russia are places where people like me go to die. Though 
arrested often, I went there three times where I watched many people like me die. My 
first time occurred after police stopped me for a bribe. I had no money so he searched 
me, found a syringe he said contained heroin, and locked me up. When I got sick from 
withdrawal symptoms and was most vulnerable, they promised “shirka” [liquid poppy 
straw extract] if I admitted to stealing something that I didn’t. I refused, spent a year in 
SIZO awaiting trial, but was finally convicted for two more years because drug users like 
me don’t stand a chance. I was shocked to learn that drug injection in SIZO and prison 
was worse than on the streets of Gatchina, where I lived. The guards helped supply 
drugs and prison leaders made sure we remained addicted. Many of us paid with our 
lives.  Some guys overdosed, others became HIV-infected like me and tuberculosis 
finished off the rest of us. Even though all of us were sick, seeing a doctor and getting 
care was nearly impossible. The bosses controlled everything. I swear the doctors were 
even worse than the guards. They just sent us back to our dorms to die.   
I was luckier than most and survived my first incarceration.  I tried to be strong 
and avoid drugs. I cut back, but I had money and connections so I still used.  I was 
weak and the prison bosses made sure I could get high and keep their pockets full. 
Within a week of release, I was back at it again. The police knew it too! They stayed on 
top of me, extracting their bribes, but once I ran out of money, I was arrested and back 
in SIZO and prison for another three years. This time, they sent me to a colony for 
seasoned criminals.  
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I developed fevers and lost a lot of weight. I was sure I would die. My family had 
money and I was able to bribe my way and eventually saw a doctor. Without money, I 
would have died like everyone else. After 6 months of coughing and 15 pounds lost, my 
money bought me a fluorogram that was suggestive of TB and I was shipped to a 
specialty TB colony. It seemed like everyone with TB also had HIV. I survived the 
scariest place I had ever been. We were 36 men in a “closet” with only 12 beds. We 
stood, coughed on each other, while others slept in shifts. Most guys, including me, 
would stop or dispose of our TB medications so that we could get sick and move from 
our “closet” to the infirmary where we’d get our own bed. Many who went to the 
infirmary never left except in a pine box because their medications didn’t work anymore.  
I must be really strong. As soon as I got out, my parents took me to the local TB 
dispensary.  Even though I told the doctors about what happened, they didn’t believe 
me and I went through the entire process again of confirming TB. I received no 
medications for several months, developed fevers, drenching night sweats and weight 
loss again before they would prescribe medications. I told them the medications had 
stopped working before, but they started me on the same ones I took before. It was no 
surprise that medications didn’t work.  
I got sicker and my parents drove me to St. Petersburg to a special hospital and 
paid a lot of money for the doctors to find me a bed, prescribe new TB medications, and 
for the first time assessed my HIV with a CD4 count.  Thankfully, my HIV was not a 
problem, but they said the TB might kill me. A doctor from the AIDS Centre said that he 
would bring me HIV medications if my parents would “donate” some money for the 
convenience. I remained connected to an IV for two months and received many TB 
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medications my parents bought.  The TB and HIV medications began to work.  My 
cough and fevers went away, I gained weight, but I went home taking an entire cup of 
pills every day for almost two years.  
I know I almost died. Daily, I crave shirka! My mom knows me and never lets me 
out of her sight. Even when I try to make excuses to get some time alone, she never 
leaves my side. She knows me. I know me too!  One minute alone and I know I will find 
shirka. If I do, I know I will get another free ticket to prison or to heaven. Either way, I 
am in prison.  I prefer the prison in my house over the one where I know nobody cares. 
* Sasha is not his real name.  
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Panel 3:  Recommendations for Prevention and Treatment Policies  
 
 Develop strategies to reduce incarceration rates in key populations. Laws and 
policies that criminalize personal drug use and sex work should be changed. New 
strategies should be developed that directly aim to reduce incarceration, especially 
to address TB transmission in PWID. Modelling here confirm the negative 
contributions of incarceration, especially on PWID, on perpetuating the HIV and TB 
epidemics. For example, current policing policies target high-risk individuals (i.e. 
PWID, registered drug users, sex workers etc.) and few provide community policing 
that focus on engaging drug users in evidence-based addiction treatment or harm 
reduction services in the community.  Development of community policing efforts, 
pre-booking diversion programs, alternatives to incarceration such as drug courts or 
community supervision in probation that favours rehabilitation and treatment over 
incarceration are needed. Quality community supervision in probation that engages 
PLH or those at risk for HIV in community settings where supportive social networks 
remain and prevention and treatment is uninterrupted is crucial.  
 
 Improve HIV Testing and Treatment Strategies: In order to meet UNAIDS policies 
for 90% detection, ART coverage and viral suppression (90-90-90), EECA prisons 
must improve HIV testing strategies because HIV identification falls far lower than 
UNAIDS targets. While some countries meet ART coverage mandates, room for 
improvement remains. Identifying HIV and increasing ART coverage within prison 
must, however, be linked to ART continuity post-release, including linkage to OAT.  
 
 Reduce gap between prison and community healthcare services. Prisoners with 
comorbid conditions have a right to the same standard of prevention and treatment 
services as those in community settings.124 SUDs should be addressed as chronic, 
recurring health conditions that should be screened for and treated by the same 
standards provided in the community. OAT programs are markedly less expensive 
than imprisonment and modelling here suggest that the most effective strategy to 
reduce HIV transition is to increase OAT coverage to PWID within prison and 
effectively transition them to OAT post-release. Where international donors fund HIV 
treatment and prevention (e.g., GFMTA, PEPFAR), these agencies should stipulate 
that such prison-based programs are both introduced and scaled-to-need as part of 
a national strategy as a requirement for continued funding.   
 
 Introduce and expand OAT, NSP and ART in CJS. Modelling of HIV transmission 
here suggests that scaling up OAT coverage to 50% combined with retention post-
release during the heightened risk period, would reduce new infections in PWID the 
most. National guidelines for HIV prevention and treatment should specifically 
stipulate equivalence of treatment in community and CJS. International agencies 
support 15 evidence-based practices in CJS.  And where such stipulations exist, 
implementation and monitoring should specifically address CJS settings. Despite the 
existence of national guidelines, there is a failure to implement a comprehensive 
drug policy in prisons that includes: psychological support, NSP, OAT, and ART. 
Crucially, the scale-up of these interventions in CJS should coincide with improving 
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continuity of care and prevention post-release – this could have substantial HIV 
prevention benefit. 
 
 
 Access to integrated care. Compared to those in the community, prisoners carry a 
higher burden of disease with multiple medical and social comorbidities that require 
a comprehensive strategy to address HIV, HCV, TB and sexually transmitted 
infections, as well as psychiatric and substance use disorders. While policies that 
favour alternatives to incarceration are preferred, for those who do interface with the 
prison environment, such settings provide an opportunity to screen, treat and 
provide continuity of care post-release to those otherwise missed by community 
prevention and treatment services.  
 
 Align Prisoner Health with International HIV Prevention and Treatment Goals: 
The 90-90-90 UNAIDS HIV prevention and treatment goal to diagnose, treat and 
achieve viral suppression in 73% of all PLH should be extended to prisoners where 
the HIV continuum of care in EECA is poorly characterized.  To achieve this goal, 
innovations in HIV testing (e.g. routine testing that has been successful in other 
settings where it was linked to treatment), provision of ART to all PLH and achieving 
viral suppression through optimal ART adherence will require not only changes in 
prison-based services, but also in transitional programs to the community.  Modelling 
here suggests that the transitional care, especially by providing OAT during 
incarceration and sustaining it post-release will be crucial to reduce HIV prevalence 
in the long-run.   
 
 Continuity of care. Prison prevention and treatment should be embedded within a 
national framework for providing continuous care within SIZO, prison and following 
community release. Our modelling suggests that providing continuity of interventions 
such as OAT post-release is key for achieving large HIV prevention benefit among 
PWID.  The CJS should be just another setting to provide care to a concentrated 
population with comorbid conditions. Partnerships with non-governmental 
organizations should be encouraged to ensure that prevention and treatment 
services are maintained.  
 
 Education. To successfully implement evidence-based screening and treatment for 
SUDs, HIV, HCV and TB, continuing education is essential to directly address and 
reduce negative attitudes toward people with SUDs and HIV in order to reduce both 
stigma and discrimination. Such professional development should not only target 
medical personnel, but also custodial staff to better align efforts to engage to 
promote health and wellness in prisoners.  
 
 Implementation of organizational strategies.   CJS administrators and staff need 
to understand that providing healthcare, especially to PWID, is the best strategy to 
reduce recidivism and improve public health.  The success of many international 
efforts to expand harm reduction strategies has been accompanied with efforts to 
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help staff understand the value of providing healthcare.  This is a long-term strategy 
to better integration of health and safety policies. 
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Table 1: Overview of Prison Population in Eastern Europe and Central Asia* 
 
 
AZE 
 
 
KAZ 
 
KYR TAJ TUR UZB RUS UKR BEL MOL LIT LAT EST ARM GEO 
Prison population 
 
~16,50
0 
44,893 10,060 
~9,00
0 
30,56
8 
~42,00
0  
656,61
8 
57,396 
31,70
0  
5,329 6,634  3,276 
2,77
5 
3,894 9,724 
Estimated Number of People Who Inject Drugs 
Community 71,283  
116,84
0  
25,000 
25,00
0  
NA 80,000 
1.8 
million 
332,50
0  
75,00
0 
30,200 5,403 
10,03
4 
9,00
0 
3,310 
45,00
0  
Prison 
31.9% 
 
— 30.4% — NA — —
**
 48.7% — — — — — 5.5% — 
Antiretroviral Therapy Coverage 
Community 14% 4,639 13% 10% NA 24% 
178,71
1 
26% 21% 17% 542 1,055 
2,99
8 
16%  39% 
Prison 63.2% 34.3% 
69.9% of 
those 
registere
d 
243 
59.1
% 
NA — 5.0% 6.4% — 63.1% 
23.2
% 
19.3
% 
— 
77.3
% 
87.5
% 
HIV prevalence 
Community 0.1% 0.2% 0.3% 0.4% 
 
<0.2
% 
0.2% 1.1% 1.2% 0.5% 0.6% 0.1% 0.7% 1.0% 0.2% 0.3% 
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Prison 3.7% 3.9% 8.4% 2.4% 
 
0 
4.7% 6.5% 19.4% — 2.6% 3.4% 
20.4
% 
14% 2.4% 
0.90
% 
TB Incidence or Prevalencea 
Community
++ 
77 99 142 91 64 82 84 94 58 153 62 49 20 45 106 
Prison 152 2,110a 145 162      184 58a 69   56 
Opioid Dependent Persons 
Community 1.5% 1.0% 0.80% 
0.54
% 
— 0.80% 2.3% 0.91% 
0.59
% 
— 
0.24
% 
0.66
% 
 
— 
0.16
% 
 
1.36
% 
 
Prison 32.5% 
3.0%**
* 
145*** 
 
5.0% — — — 44.3% — 
6.6%**
*  
7.6% 
30.0
% 
— — — 
Opioid Agonist Therapy Sites  (N) 
Community 2 10 23 6 NA NA NA 169 19 3 23 10 9 10 21 
Prison NA NA 7 NA NA NA NA NA NA 9 NA 9 4 9 2+ 
Opioid Agonist Therapy Coverage (N) 
Community 137  205 1,227 677 NA NA NA 8,264 1,066 392 930 
 
424 
919 430 2,600 
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Prison NA NA 400 NA NA NA NA NA NA 68 NA 26 56 151 — 
 
Countries: AZE: Azerbaijan; KAZ: Kazakhstan; KYR: Kyrgyzstan; TAJ: Tajikistan; TUR: Turkmenistan; UZB: Uzbekistan; RUS: 
Russia; UKR: Ukraine; BEL: Belarus; MOL: Moldova; LIT: Lithuania; LAT: Latvia; EST: Estonia; ARM; Armenia; GEO: Georgia.  
 
*All values are from the survey administered for this study in collaboration with UNODC and refer to 2015, unless 
otherwise specified in the online appendix.  
**A cell is left blank if the information was not filled out or unavailable; NA signifies that the service is not provided.  
***Refers only those officially registered as opioid dependent with the National Narcological Registry. 
+Present only as a pilot program in SIZO (pre-trial detention) for detoxification and not for maintenance therapy  
++per 100,000 people 
Legend: OAT: opioid agonist therapies; ART: antiretroviral therapy; PWID: people who inject drugs 
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Table 2:  Overview of the policies and practices related to HIV infection and harm reduction services in prisons of Eastern 
Europe and Central Asia1,2 
 
 AZE KAZ KYR TAJ TUR UZB RUS UKR BEL MOL LIT LAT EST ARM GEO 
Ministry 
overseeing 
prisoner 
health 
Justice Interio
r 
Priso
n 
Justic
e 
Interi
or 
Interio
r 
Priso
n 
Priso
n 
Interi
or 
Justic
e 
Justic
e 
Justic
e 
Justic
e 
Justic
e 
Priso
n 
Prisons, N 35 76 
 
11 13 14 42  146 
 
 12 7 11  12 15 
Male 16 69 10 12 12 39  131  10 6 10  11 11 
Female 1 6 1 1 1 1  15  1 1 1  1 1 
Prisoners, N ~16,50
0- 
44,89
3 
7,961 ~9,00
0 
30,56
8 
~42,00
0 
 57,39
6 
 5,329 6,643 3,276 2,775 3,894 9,724 
Women, % 2.8 7.7 4.0 3.3 24.8 3.0  5.6  6.6 3.7 7.4  4.5 3.3 
Incarceration 
rate+ 
236 231 181 130 583 152 446 193 306 215 268 239 218 132 274 
Occupancy 
rate, % 
81.4 71.8 55.5 61.5 85.0 80.0 94.2 120.2
4 
96.8 102.9 83.1 59.5 96.3 89.3 47.8 
NSP No No Yes Yes No No  No  Yes No No  Yes No 
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Start date   2005 2010      1999    2004  
Facilities   10 1      10    9  
OAT No No Yes No No No  No  Yes No Yes  Yes No 
Start date   2008       2005  2012  2011  
Facilities   7       9  9  9  
People   400       68  26  151  
Detoxification 
with 
methadone or 
buprenorphine 
No No No N N No  No  Yes No No  No Yes 
Non-
pharmacologi
cal 
detoxification 
Yes No Yes No NA No  Yes  No Yes Yes  Yes No 
HIV testing & 
counselling 
Yes Yes Yes Yes Yes3 Yes  Yes  Yes Yes Yes  Yes Yes 
Start date  1997 2001 2003  2003  2006  2008  1994  2004 2004 
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Condom 
provision 
Yes Yes Yes Yes No No  Yes  Yes  Yes No   Yes 
Start date 2011 2002 2005 2003    2008  1999 2004    2004 
ART Yes Yes Yes Yes No Yes  Yes  Yes Yes Yes  Yes Yes 
Start date 2007 2005  2007  2008 2008 2004 1998 2005 2005 
TB 
fluorography 
Yes Yes Yes Yes Yes Yes  Yes  Yes Yes Yes  Yes Yes 
Start date 1995 1998 1997   1991  1996 2011 2004 1998 
TB treatment Yes Yes Yes Yes Yes3 Yes  Yes  Yes Yes Yes  Yes Yes 
Start date 1995  1998   2004  1996 1998   1998 
HCV 
diagnostics 
Yes Yes Yes Yes NA Yes  No  Yes Yes Yes  No Yes 
Start date 2006  2005 2015     2004  2014 
Treatment of 
HCV 
No No No No NA No  No  No Yes 
(acute 
only) 
No  No Yes 
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HBV 
diagnostics 
No Yes Yes   Yes  No  Yes No Yes  No Yes 
Treatment of 
HBV 
No No No   Yes  No  No No Yes  No No 
HBV 
vaccination 
No No No   No  No  No No No  No No 
Programs on 
prevention of 
physical and 
sexual 
violence 
Yes Yes No   Yes  No  No  No   Yes 
Staff 
protection 
program 
against HIV as 
an 
occupational 
hazard 
No Yes Yes   Yes  Yes 
 
 Yes Yes Yes  No Yes 
Post-exposure 
prophylaxis 
No Yes Yes Yes  Yes  No  Yes No No  No No 
Start date   2010             
Diagnosis & 
treatment of 
STIs 
Yes Yes Yes   Yes  Yes  Yes  Yes  Yes Yes 
 
Legend:  ART=antiretroviral therapy; OAT=opioid agonist therapy; STIs=sexually transmitted infections 
 
Countries: AZE: Azerbaijan; KAZ: Kazakhstan; KYR: Kyrgyzstan; TAJ: Tajikistan; TUR: Turkmenistan; UZB: Uzbekistan; RUS: 
Russia; UKR: Ukraine; BEL: Belarus; MOL: Moldova; LIT: Lithuania; LAT: Latvia; EST: Estonia; ARM; Armenia; GEO: Georgia.  
  
*All values are from the survey administered for this study in collaboration with UNODC and refer to 2015, unless 
otherwise specified.  
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2 A cell is left blank if the information was not completed in the survey.  
3 “People,” “treated,” and “tested” refer to the total number of people receiving service in 2014.    
4 Available only as a pilot project.  
5 Women and juveniles housed in the same facility. 
6 Refers to incident cases 
+ (Number of prisoners per 100,000 population) 
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Figure 1: An overview of the criminal justice system in Eastern Europe and Central Asia 
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Figure 2:  Relationship of the risk environment in community and criminal justice settings in Eastern Europe and Central 
Asia 
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Figure 3: Projected median trends in HIV prevalence (a,b) and incidence (c,d) among 
community (both never and previously incarcerated PWID) and incarcerated PWID in 
Ukraine for various incarceration and intervention scenarios* 
 
   * Scenarios shown are for the status quo (solid black line), and if there was either: no 
effect of incarceration on transmission risk after 2015 (short dashed line); no further 
incarceration of PWID after 2015 (long dashed line); or 50% of incarcerated PWID were 
initiated on OAT each year starting from 2015 and maintained on OAT for a year after 
release (long dash-dot line). Data points with 95%CI are shown for comparison and 
shading represents the 95% credibility intervals for the status quo projection (light 
shading) and if incarceration had no effect on transmission risk after 2015 (dark 
shading).  
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Figure 4: Percentage of new HIV infections that would be averted over 15 years (from 
2015 and 2030) if either (a) incarceration no longer elevated transmission risk (full and 
conservative projections); (b) there was no further new incarceration of PWID; or (c) 
prison OAT was scaled up with or without retention after release. Bars show the median 
projections, while error bars show the 95% credibility intervals. 
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Figures 5: Association between number of years incarcerated and prevalence of ever 
having TB among prisoners (5A) and people who inject drugs in the community (5B) in 
Ukraine. The points are the mean proportion of prisoners (Figure 5A) or community 
PWID (Figure 5B) reporting ever having TB for different reported years in prison, and 
the error bars are the 95% bootstrapped confidence intervals about the mean. The solid 
black line is the best logistic fit to the data, and the grey shaded area is bounded by the 
best logistic fits to the lower and upper confidence bounds of the data. 
5A. Prisoners in Ukraine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Data derived from a 2011 PUHLSE national prison survey39,45.  
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5B. Community People Who Inject Drugs in Ukraine 
 
* Data derived from a multi-site ExMAT survey of people who inject drugs in Ukraine in 
2015.   
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Figure 6: Incarceration Rates in Eastern European and Central Asian Countries and Availability of Opioid Agonist 
Therapies and Needle/Syringe Programs  
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